[The "Historic Study" SOLIDARITY-Research's Answer to the Sars-CoV-2 Pandemic]

NTM. 2020 Jun;28(2):219-225. doi: 10.1007/s00048-020-00257-5.
[Article in German]

Abstract

This paper is part of Forum COVID-19: Perspectives in the Humanities and Social Sciences. The novel coronavirus (Sars-CoV-2) poses a huge challenge to the world community. Knowledge about the virus and its properties is limited, but there is a great need to base political and medical decisions on scientific knowledge. This situation is leading to a dynamization of research. A prominent example of such a development is SOLIDARITY. The epistemological dimensions of this trial, which is coordinated by the WHO, and the resulting ethical implications are discussed in this article.

Dieser Beitrag ist Teil des Forums COVID-19: Perspektiven in den Geistes- und Sozialwissenschaften. Das neuartige Coronavirus (Sars-CoV-2) stellt die Weltgemeinschaft vor eine große Herausforderung. Das Wissen über das Virus und seine Eigenschaften ist lückenhaft, aber der Bedarf, politische und medizinische Entscheidungen an wissenschaftlicher Erkenntnis auszurichten ist groß. Diese Lage führt zu einer Dynamisierung der Forschung. Ein prominentes Beispiel ist die WHO-Studie SOLIDARITY. Die epistemologischen Besonderheiten und die daraus resultierenden ethischen Implikationen werden in diesem Beitrag näher beleuchtet.

Keywords: COVID-19; Evidence-based medicine; Research ethics; SOLIDARITY; WHO.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenosine Monophosphate / analogs & derivatives
  • Adenosine Monophosphate / therapeutic use
  • Alanine / analogs & derivatives
  • Alanine / therapeutic use
  • Antiviral Agents / therapeutic use*
  • Betacoronavirus*
  • Bioethical Issues
  • COVID-19
  • Chloroquine / therapeutic use
  • Clinical Trials as Topic* / ethics
  • Clinical Trials as Topic* / organization & administration
  • Coronavirus Infections / drug therapy*
  • Coronavirus Infections / epidemiology*
  • Drug Combinations
  • Editorial Policies
  • Humans
  • Hydroxychloroquine / therapeutic use
  • International Cooperation
  • Lopinavir / therapeutic use
  • Pandemics*
  • Pneumonia, Viral / drug therapy*
  • Pneumonia, Viral / epidemiology*
  • Research Design
  • Ritonavir / therapeutic use
  • SARS-CoV-2
  • World Health Organization

Substances

  • Antiviral Agents
  • Drug Combinations
  • lopinavir-ritonavir drug combination
  • Lopinavir
  • remdesivir
  • Adenosine Monophosphate
  • Hydroxychloroquine
  • Chloroquine
  • Ritonavir
  • Alanine